Tagungen und Workshops zum Thema Onkologie

European Molecular Biology Organization – EMBO

The most important factor that limits the success of anti-cancer therapy is the emergence of drug resistance. At a time where we seem to have reached a limit in terms of genetic mutation driven-treatment efficacy in multiple cancer types, i.e. with a best overall survival around 30-36 months in melanoma but still more than one third of deaths after two years, there is an urgent international need for innovative strategies to combat the resistance. The milestone discovery of drug-tolerant cancer persistent cells suggests that drug resistance might derive from genetically similar clones. Indeed, advances during the past decade show that persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. This workshop will provide a unique opportunity to promote communication among biologists, mathematicians and clinicians, which will enable interdisciplinary discussions and collaborations for this fasting emerging domain. The sessions will start with understanding molecular mechanisms of cancer persistence, and will continue with discovering therapeutic targets of persistent cells, deciphering their heterogeneity at single cell level, learning from the microbial persister world, and modelling of the dynamics of persistent cells.

The programme includes teaching lectures, case presentations, panel discussions, as well as hands-on workshops. You will have the opportunity to gain knowledge on latest clinical and technical aspects of cancer imaging, to share experience, to discuss critical issues and open questions, and get support how to improve your day-to-day practice. And most importantly, you will have the opportunity to exchange ideas and make contacts within the community, colleagues and experts in different areas of cancer imaging. We hope that you will take this opportunity to establish new friendships and rekindle old ones. Enjoy the in person meeting in the beauties and charms of Dubrovnik and the Adriatic.

Email: office@esoi-society.org

European Association For Cancer Research (ECAR)

Cancer Genomics 2022 is the fifth EACR conference on this topic, and it is now widely recognised as the premier European conference dedicated to cancer genomics. In 2022, after a 3-year break, it will again cover the latest exciting developments: single cell and spatial analysis of cancers, cancer immune genomics, data integration and convergence, DNA methylation, genomic instability and ctDNA. Featuring an exceptional international faculty, extensive networking opportunities and a limited number of in person participants, this conference will provide both the possibility and intimate setting for top quality scientific interaction. We look forward to welcoming you to Oxford for this exciting meeting!

FOMF - Forum für medizinische Fortbildung

Zertifizierte Fortbildung für ärztliche Fachkräfte der Immunonkologie, Hämatologie und Onkologie vor Ort in München oder via Livestream, 08. - 09.07.2022. Updates & die neuesten Leitlinien. 16 CME-Punkte werden bei der zuständigen Ärztekammer angefragt. Jetzt informieren & buchen! Der zweitägige Refresher-Kurs ist DIE Veranstaltung, um die neuesten Entwicklungen und Daten für die wichtigsten hämato/onkologischen Erkrankungen zu erfahren. Unter anderem werden auch die neuesten Entwicklungen bei CAR-T Cells diskutiert. Die eingeladenen Referentinnen und Referenten zeichnen sich durch Fachexpertise/Meinungsbildung für die einzelnen Tumorentitäten aus und referieren auch über die neuesten Daten des ASCO 2022. Hierzu werden in 16 wissenschaftlichen Referaten die aktuellsten Studienergebnisse der Behandlungen nach dem ASCO-Kongress vorgestellt, aber auch die Wirkungsweisen und Nebenwirkungen der neuen Therapien erörtert.

Nach jedem Vortrag haben Sie die Gelegenheit mit den deutschen, österreichischen und schweizerischen Expertinnen und Experten zu diskutieren und sich kollegial auszutauschen. Ihre Fragen können Sie gerne vor Ort oder via Livestream stellen. Hierfür ist ausreichend Zeit vorgesehen, auch z.B. für Fragen zur Behandlung Ihrer Problemfälle.

Der zweitägige Refresher-Kurs in dem neuen Format ist kompakt, informativ und up-to-date und bietet Ihnen eine hervorragende Grundlage als Fort-, Aus- und Weiterbildung für Ihre Tätigkeit in Praxis, Klinik oder für die Hämatologie- / Onkologieprüfung.

Veranstaltungskoordination;     Tel.: [+43 2252 2632 6310];     Email: info@fomf.at

Immunologie, Onkologie, Hämatologie, Pharmakotherapie IO & Gezielte Therapien, Metastasierte gynäkologische Karzinome, Blasen-/Nierenzellkarzinome, Ösophagus-/Magenkarzinome, Non-Hodgkin Lymphome, Liquid Biopsy in Klinik und Forschung, Myeloproliferative Neoplasien / Mastozytose, Metastasierte kolorektale Karzinome, Derma-Onkologie, AML/MDS, Nicht-kleinzelliges Lungenkarzinom, CAR-T-Zellen Update, Kopf-Hals-Karzinome, Hepato-Biliäre Karzinome, Multiples Myelom, Nebenwirkungen der IO/GT und ihre Therapie

Fortbildung für Gesundheitsfachberufe (CME),    Immunologie und Allergie

FOMF - Forum für medizinische Fortbildung

Zertifizierte Fortbildung für ärztliche Fachkräfte der Immunonkologie, Hämatologie und Onkologie vor Ort in München oder via Livestream, 08. - 09.07.2022. Updates & die neuesten Leitlinien. 16 CME-Punkte werden bei der zuständigen Ärztekammer angefragt. Jetzt informieren & buchen!

Der zweitägige Refresher-Kurs ist DIE Veranstaltung, um die neuesten Entwicklungen und Daten für die wichtigsten hämato/onkologischen Erkrankungen zu erfahren. Unter anderem werden auch die neuesten Entwicklungen bei CAR-T Cells diskutiert.

Die eingeladenen Referentinnen und Referenten zeichnen sich durch Fachexpertise/Meinungsbildung für die einzelnen Tumorentitäten aus und referieren auch über die neuesten Daten des ASCO 2022. Hierzu werden in 16 wissenschaftlichen Referaten die aktuellsten Studienergebnisse der Behandlungen nach dem ASCO-Kongress vorgestellt, aber auch die Wirkungsweisen und Nebenwirkungen der neuen Therapien erörtert.

Nach jedem Vortrag haben Sie die Gelegenheit mit den deutschen, österreichischen und schweizerischen Expertinnen und Experten zu diskutieren und sich kollegial auszutauschen. Ihre Fragen können Sie gerne vor Ort oder via Livestream stellen. Hierfür ist ausreichend Zeit vorgesehen, auch z.B. für Fragen zur Behandlung Ihrer Problemfälle.

Der zweitägige Refresher-Kurs in dem neuen Format ist kompakt, informativ und up-to-date und bietet Ihnen eine hervorragende Grundlage als Fort-, Aus- und Weiterbildung für Ihre Tätigkeit in Praxis, Klinik oder für die Hämatologie- / Onkologieprüfung.

Veranstaltungskoordination;     Tel.: [+41 41567 2980];     Email: info@fomf.ch

Pharmakotherapie IO & Gezielte Therapien, Metastasierte gynäkologische Karzinome, Blasen-/Nierenzellkarzinome, Ösophagus-/Magenkarzinome, Non-Hodgkin Lymphome Liquid Biopsy in Klinik und Forschung, Myeloproliferative Neoplasien / Mastozytose Derma-Onkologie AML/MDS Pause Nicht-kleinzelliges Lungenkarzinom CAR-T-Zellen Update, Kopf-Hals-Karzinome, Hepato-Biliäre Karzinome, Multiples Myelom, Nebenwirkungen der IO/GT und ihre Therapie

Immunologie und Allergie,    Hämatologie

FOMF - Forum für medizinische Fortbildung

Zertifizierte Fortbildung für ärztliche Fachkräfte der Immunonkologie, Hämatologie und Onkologie vor Ort in München oder via Livestream, 08. - 09.07.22. Updates & die neuesten Leitlinien. 16 CME-Punkte werden bei der zuständigen Ärztekammer angefragt. Jetzt informieren & buchen! Der zweitägige Refresher-Kurs ist DIE Veranstaltung, um die neuesten Entwicklungen und Daten für die wichtigsten hämato/onkologischen Erkrankungen zu erfahren. Unter anderem werden auch die neuesten Entwicklungen bei CAR-T Cells diskutiert. Die eingeladenen Referentinnen und Referenten zeichnen sich durch Fachexpertise/Meinungsbildung für die einzelnen Tumorentitäten aus und referieren auch über die neuesten Daten des ASCO 2022. Hierzu werden in 16 wissenschaftlichen Referaten die aktuellsten Studienergebnisse der Behandlungen nach dem ASCO-Kongress vorgestellt, aber auch die Wirkungsweisen und Nebenwirkungen der neuen Therapien erörtert.

Nach jedem Vortrag haben Sie die Gelegenheit mit den deutschen, österreichischen und schweizerischen Expertinnen und Experten zu diskutieren und sich kollegial auszutauschen. Ihre Fragen können Sie gerne vor Ort oder via Livestream stellen. Hierfür ist ausreichend Zeit vorgesehen, auch z.B. für Fragen zur Behandlung Ihrer Problemfälle.

Der zweitägige Refresher-Kurs in dem neuen Format ist kompakt, informativ und up-to-date und bietet Ihnen eine hervorragende Grundlage als Fort-, Aus- und Weiterbildung für Ihre Tätigkeit in Praxis, Klinik oder für die Hämatologie- / Onkologieprüfung.

Veranstaltungskoordination;     Tel.: [+49 6192 4707 200];     Email: info@fomf.de

Immunonkologie, Hämatologie, Onkologie, Pharmakotherapie IO & Gezielte Therapien, Metastasierte gynäkologische Karzinome, Blasen-/Nierenzellkarzinome, Ösophagus-/Magenkarzinome, Non-Hodgkin Lymphome, Liquid Biopsy in Klinik und Forschung, Myeloproliferative Neoplasien / Mastozytose, Metastasierte kolorektale Karzinome, Derma-Onkologie, AML/MDS, Nicht-kleinzelliges Lungenkarzinom, CAR-T-Zellen Update, Kopf-Hals-Karzinome, Hepato-Biliäre Karzinome, Multiples Myelom, Nebenwirkungen der IO/GT und ihre Therapie

Fortbildung für Gesundheitsfachberufe (CME),    Immunologie und Allergie

European Society of Medicine

We are working relentlessly to assemble a scientific program which showcases the latest knowledge in an interactive and modern platform. With over 400 speakers across 3 days, the 2022 ESEMD General Assembly is the place to be for medical professionals in Europe and beyond.

Office;     Email: office@esmed.org

2022 ESEMD General Assembly, European Society of Medicine

Epidemiologie,    Neurologie

European Molecular Biology Organization – EMBO

We are living in an extremely interesting period in cancer research. Knowledge gained in the last decades is now entering the clinic and new findings are translated into the clinic at a pace never seen before. Most of the successes come from our understanding of basic processes that govern cancer initiation and progression, including signal transduction. Consequently, we see that especially inhibitors to signalling molecules, in particular kinases, are entering the clinic very rapidly. Therefore, the molecular mechanisms by which signals are received by cells, transduced towards the proper targets and integrated into a biological response is amongst the most-studied areas in modern biology. In this EMBO|FEBS Lecture Course we are bringing together a number of true experts in the field from basic and translational oncology. This MBO|FEBS Lecture Course will cover signalling by various pathways (PI3K, WNT, RAS/RAF) but also DNA damage and protein degradation signalling. We will also cover the consequences of pathway deregulation for cellular processes like metabolism and damage repair. Finally, the application or translation of this knowledge into the clinic will be discussed by the speakers.

TMC Academy

In just 3 short days, benefit from the vast expertise of MSK radiologist Dr. Rachel Gerson as she introduces participants to MR assessment of bone marrow signal and of bone and soft tissue tumours, through a series of key lectures followed by group case demos and discussions.

Tel.: [+34935500750];     Email: academy.info@telemedicineclinic.com

Radiology, Bone, Tumours, MSK

Radiologie, Nuklearmedizin und Radiotherapie,    Fortbildung für Gesundheitsfachberufe (CME)

Binaytara Foundation

The “2022 Cellular Therapy Conference” is a CME-accredited activity with in-person and virtual formats featuring leading experts in cellular therapies. The goal of this activity is to improve the knowledge, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients receiving cellular therapies for hematologic and non-hematologic disorders. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in chimeric antigen receptor (CAR) based therapies. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Development and Events Assosciate;     Tel.: [4255575953];     Email: keegan.o@binayfoundation.org

Oncology, Cellular therapy, Hematology, Education, Continuing education, CME, MOC, Cancer, Charity

Conventus Congressmanagement & Marketing GmbH

Email: conferencemarketing@conventus.de

European Molecular Biology Organization – EMBO

FomF - Forum für medizinische Fortbildung

Das Onko Experten-Forum Gastrointestinal findet amDas Onko Experten-Forum Gastrointestinal findet am 21. September in in Form eine WebUps via Livestream statt. Es erwarten Sie Impulsvorträge, Fallbesprechungen sowie Empfehlungen zu Behandlungsrichtlinien. 3 CME-Punkte sind bei der zuständigen Ärztekammer angefragt. Jetzt informieren & buchen, die Teilnahme ist kostenlos!

Veranstaltungsorganisation;     Tel.: [+4961924707200];     Email: info@fomf.de

Fortbildung für Gesundheitsfachberufe (CME),    Gastroenterologie

Feliks Skubiszewski Foundation for the Advancement of Surgery

We kindly invite you to the 3rd edition of the Congress concerning minimally invasive surgery in various treatment disciplines. The lecturers of the Congress are the best world-class experts in their specializations. We invite surgeons of various specialties - general surgery, bariatric surgery, oncology, thoracic surgery, urology, gynecology, vascular surgery, neurosurgery, as well as doctors in the course of specialization.

Email: info@czelej.com.pl

surgery congress, congress of Minimally Invasive Surgery

Wikonect GmbH

Wikonect GmbH;     Tel.: [+49 611 204809 0];     Email: info@wikonect.de

European Society for Translational Medicine (EUSTM)

The European Society for Translational Medicine (EUSTM) cordially invites you to attend the 9th Annual Congress of the European Society for Translational Medicine on Immunotherapeutics – From Biology to Patient Care (EUSTM-2022) held in virtual format during 3-5 October, 2022. Due to the COVID-19 Corona virus pandemic, the European Society for Translational Medicine (EUSTM) has revised the 2022 congress format to a virtual event. EUSTM took this initiative to ensure the health and safety of our global delegates. This Congress will focus on recent advances in the field of immunotherapeutics for solid tumors, hematological malignancies, autoimmune disorders, infectious disease, Covid, & vaccines covering from biological research, diagnostics & biomarkers to clinical care. EUSTM-2022 not only provides a unique platform for scientific exchange and discussion about the recent progress in both bench and bed side of immunotherapies for cancer and infectious diseases, but also an avenue for global networking with key stakeholders in academic research, clinical care giver, public health workers, and industrial leaders.

European Society for Translational Medicine;     Tel.: [+43 1 8923 562];     Email: eustm-2022@eutranslationalmedicine.org

solid tumors, hematological malignancies, autoimmune disorders, infectious disease, Covid, vaccines, Translational Medicine, Medicine, Immunotherapeutics, Immunobiology, biological research, diagnostics & biomarkers, clinical care, Celular Biology, Molecular Biology, Blood Cancer, Atopic Dermatitis, Public Health

Immunologie und Allergie,    Infektiologie

Binaytara Foundation

The 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies.

Media Outreach;     Tel.: [425-557-5953];     Email: keegan.o@binayfoundation.org

Oncology, Hematology, Cancer, Equity in Cancer Care, Binaytara Foundation, Research, Academic, Peer-reviewed, Group-think

European Association For Cancer Research (ECAR)

The study of cancer metabolism has changed our view of tumour biology. Cancer and stromal cells alter their metabolic wiring in order to meet the energetic and anabolic demands, to cope with external insults, to survive in hostile environments and to alter the molecular properties of the niche they inhabit. In this context, it is not surprising that genomic and cellular signalling perturbations have profound consequences on the metabolic landscape. The 2nd EACR Conference on Cancer Metabolism will gather top experts in the field to discuss the metabolic alterations in tumours and how we can exploit it to treat cancer. The city of Bilbao in Spain will continue to host the conference and bring together excellent research and a unique environment.

Core metabolic alterations in tumours, Cancer metabolism and the control of the epigenome, Cancer metabolism beyond the tumour cell, Emerging cancer metabolism-based therapeutic strategies, Technological advances in cancer metabolism

Molekularbiologie,    Biologie

We are pleased to announce that the Australasian International Breast Congress will be held jointly with the Australasian Society for Breast Disease (ASBD), 6th World Congress on Controversies in Breast Cancer (CoBrCa) and Breast Surgeons of Australia and New Zealand (BreastSurgANZ). After all the disruptions due to COVID19, this most important congress will take place in Brisbane, Australia October 13-15, 2022. As the main congress in the field of breast diseases in the Asia-Pacific region in 2022, it is one that should not be missed

Breast cancer genetics, Breast imaging, DCIS, HER2, Immunotherapy, Oncology, Radiation, Radiotherapy, Reconstruction, Screening, Surgery, Triple negative breast cancer, Breast Cancer, ASBD, CoBrCa, BreastSurgANZ

ESMO - European Society for Medical Oncology

MAP is the leading global meeting dedicated to precision oncology, defined as molecular profiling of tumours to identify targetable alterations. This oncology field is fast evolving and has now entered the mainstream of clinical practice.

At MAP 2022, international key opinion leaders will explain how to use genomic data for treating cancer patients, matching such data to a specific drug or therapy, based on the genetic drivers detected in the patients’ tumours, and they will debate about the future challenges in precision oncology.

ESMO Registration Office;     Tel.: [+41 (0)91 973 19 13];     Email: registration@esmo.org

cancer biology, translational research, molecular pathology, clinical research, immunotherapy, personalised cancer medicine, precision medicine, tumour immunology, anticancer agents, basic science, biological therapy, laboratory medicine, genetic counselling, tumour response evaluation, imaging, molecular imaging

Translationale Medizin, Klinische Studien,    Pharmakogenomik, Personalisierte Medizin

Champalimaud Foundation

Cancer initiation and progression are orchestrated through local and systemic interactions between tumour and tumour-associated cells. A more detailed characterisation of these interactions has so far contributed to a new generation of antitumour strategies and to improved cancer prognosis. However, although we have gained increasing knowledge about the cellular and molecular constituents of tumour-promoting and tumour-suppressing microenvironments, an accurate map delineating the role of each of these constituents remains unavailable. By bringing together experts who have greatly contributed to our understanding of the tumour microenvironment, the Champalimaud Research Symposium 2022 (#CRSy22) will provide access to the most recent developments in basic and clinical research in this complex area. CRSy22 will take the form of a single-track scientific meeting with 18 invited speakers, talks selected from abstracts and 2 poster sessions, among other networking and social activities. The hybrid format will give delegates the option to attend and present their work either in-person or online.

Events Team;     Email: symposium@research.fchampalimaud.org

Tumour Microenvironment, Cancer Research, Cancer Initiation, Metabolism, Cancer Progression, Metastasis, Therapy, Cancer Immunity

Centro Nacional de Investigaciones Oncológicas (CNIO)

Recent progress will be presented during the conference to provide a forum of discussions on nutrient-sensing pathways and mechanisms, their effect in cellular function and tissue homeostasis, and the effect of their dysregulation in cancer development and metabolic disorders. The following topics will be covered: Cellular Metabolic Pathways; Energetics and Disease; Diet and Cell Metabolism ; Diet, Nutrition and Metabolic Disease.

CME Congresses

We are happy to announce the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), Hybrid Congress which will take place October 27-30, 2022 in Berlin, Germany, and online. We are planning to hold the congress as a hybrid edition (with both face-to-face and virtual components). COSTEM is moving to become an annual event as we feel it is important to build a platform for our community to interact with each other and to share our scientific research, clinical experience, and on-going developments in our field. COSTEM encourages active participation in debate discussions, and challenges global experts to promote their positions on a wide range of burning issues – providing clinicians the opportunity to share, express and compare experiences to establish and advance effective and reliable patient treatments. The 7th COSTEM Congress will continue to push the envelope and be a progressive, compelling, and informative conference. As in the past, COSTEM continues to serve as a unique platform, where the most compelling and controversial topics facing clinicians in these fields are presented in a fascinating and exciting debate forum.

Email: costem@cme-congresses.com

• CAR-T cell therapy • Haploidentical stem cell transplantation • Cellular therapy • Transplantation • GVHD prevention and treatment • Cord blood transplantation • Mesenchymal stem cell • Acute leukemia • Myelodysplastic syndrome • Multiple myeloma • Hodgkin and Non-Hodgkin lymphoma • Myeloproliferative neoplasm • Virus specific T Cell therapy • NK Cell therapy • Microbiome • Genome editing and gene therapy • Bone marrow failure syndrome • Bi-specific antibodies • CMV infection • Toxicity post transplantation (VOD, TMA etc)

Hämatologie,    Fortbildung für Gesundheitsfachberufe (CME)

Bioevents Ltd

Euroleuk2022 will continue to provide clinicians and biologists with state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field.

Tel.: [+442030514032];     Email: ilana@bioevents-congress.com

• Biology of ALL, AML, CML, CLL • Leukemia stem cells (LSCs) • Routing diagnosis gene expression and mutational profiling • Allogeneic hematopoietic stem cell transplantation • Front-line treatment of ALL, AML, CML, CLL • Treatment of resistant/relapsed disease • How novel agents are changing the treatment landscape of ALL, AML, CML, CLL • Immunotherapy • Minimal residual disease

Hämatologie,    Stammzellforschung und -therapie

Deutsche Krebsgesellschaft e. V. (www.krebsgesellschaft.de) und Stiftung Deutsche Krebshilfe (www.krebshilfe.de)

Erfolge in der Krebstherapie hängen auch von der Qualität der einzelnen Schnittstellen ab. Ein schneller Transfer – gesicherter medizinischer Innovationen von Forschung in die Versorgung - ist eine wichtige Voraussetzung für den onkologischen Fortschritt. Die Schnittstelle und Zusammenarbeit aus verschiedenen ärztlichen Fächern und Gesundheitsberufen sowie Patient*innen ist ebenfalls sehr bedeutsam.

Deutsche Krebsgesellschaft e. V. - Frau Janina Henne;     Tel.: [+49 30 3229329-21];     Email: dkk2022@krebsgesellschaft.de

Tumormedizin, Krebsforschung, Krebserkrankungen, Tumorarten, Hilfe/Selbsthilfe, Psychoonkologie, Palliativmedizin, Kommunikation, Gesundheitspolitik

Hämatologie,    Medizin (allgem.), Innere Medizin

Fraunhofer Institute for Cell Therapy and Immunology and the University Cancer Center of the University Hospital Leipzig

The Leipzig Immune ONcology (LION) Conference will bring together clinicians, scientists and industry to discuss latest developments in immune oncology. This year’s focus will be on tumor microenvironment, cell-based therapy in hematology and oncology, precision medicine addressing tolerance and inflammation, immune checkpoint inhibitors, biomarkers, and cancer vaccines. You are invited to submit an abstract of your scientific work to be presented virtually as a poster at LION 2022. We are looking forward to welcoming you virtually at the Leipzig Immune ONcology (LION) Conference on November 22-23, 2022.

Fraunhofer Institute for Cell Therapy and Immunology;     Tel.: [+49 341 35536-9320];     Email: info@lion-conference.com

oncology, immunology, hematology, biomarkers, immunotherapy, cell therapies, cancer vaccines

Hämatologie,    Immunologie und Allergie

ESMO - European Society for Medical Oncology

The ESMO Asia Congress is the annual event where global and Asian cancer professionals come together, to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level, and for the Asia-Pacific region.

ESMO Registration Office;     Tel.: [+41 (0)91 973 19 13];     Email: registration@esmo.org

Medical oncology, clinical oncology, surgical oncology, radiation oncology, oncology research, clinical practice guidelines, Pan-Asian Guidelines Adaptation

Translationale Medizin, Klinische Studien,    Pharmakogenomik, Personalisierte Medizin

The European Association for the Study of the Liver (EASL)

Fusion Conferences

This meeting will involve leaders in the field who study the biological basis of breast cancer, develop approaches for patient stratification, run clinical trials or develop new medicines for patients with breast cancer.

Fusion Conferences

This conference will focus on three major areas: First, it will present new approaches to generate precise and complex genetic alterations in mice and other animals to better “humanize” models and allow for in vivo studies of cancer gene function. Second, it will highlight studies to investigate fundamental mechanisms of cancer initiation and progression, including the cell of origin of tumors, their evolution, their metabolism, and their interactions with the immune system. Finally, the meeting will explore how genetically engineered animal models can help evaluate the efficacy of novel therapeutic approaches and to decipher mechanisms of therapeutic resistance.

Molekularbiologie,    Biotechnologie

Conventus Congressmanagement & Marketing GmbH

Email: conferencemarketing@conventus.de

Bio Ascend LLC

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) is a biennial meeting focused solely on advancing the understanding and treatment of chronic lymphocytic leukemia (CLL) and related lymphoproliferative disorders. Founded in 1979, iwCLL is now the largest international meeting dedicated to advancing state-of-the-art and emerging concepts—from laboratory-based research to the clinic—in the pathobiology and treatment of these blood cancers. The biennial meeting is intended to provide a forum that promotes the exchange of information and encourages collaboration among international leaders and scientists interested in CLL and lymphoproliferative disorders in one location for 4 days every other year.

Chronic lymphocytic Leukemia, ( CLL)

Fortbildung für Gesundheitsfachberufe (CME),    Hämatologie

Conventus Congressmanagement & Marketing GmbH

Conventus Congressmanagement & GmbH;     Email: conferencemarketing@conventus.de